Roche reported two Phase III victories for its BTK inhibitor in different multiple sclerosis populations, with the drug meeting primary endpoints and showing efficacy across relapsing and primary progressive forms in registrational studies. The company characterized the results as a breakthrough for the BTK class and said it will pursue regulatory filings based on the datasets. Roche emphasized safety monitoring and data depth in its communication, addressing earlier safety questions for the BTK class. Industry analysts noted the wins could reset treatment options for MS and challenge incumbents if regulators accept the evidence for approval across indications. The outcomes mark a notable recovery for BTK programs, highlighting how targeted kinase inhibitors continue to expand beyond oncology into neuro‑inflammatory diseases.